Shanghai Newsummit Biopharma Group Co., Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Shanghai Newsummit Biopharma Group Co., Ltd
Jeffrey Patrick joins Ohio State's effort to develop cancer drugs from internal research, bringing a biopharma viewpoint to optimizing such programs before the deal-making effort starts. Plus, the EMA sets a framework for academic interaction, and more tech transfer news.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
- Contract Research, Toxicology Testing-CRO
- In Vitro Diagnostics
- Medical Devices
- Large Molecule
- Other Names / Subsidiaries
- Newsummit Biopharma Holdings Ltd.
- Shanghai Newsummit Group
- Shanghai Newsummit Biopharma Co., Ltd
- Shanghai Newsummit Co.,
- Newsummit Biopharma Holdings Limited